Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa

Journal of Hospital Infection

Volumn 83, Issue 2, 2013, Pages 153-155

  Nakamura, A ^a   Miyake, K ^b   Misawa, S ^a   Kuno, Y ^a   Horii, T ^a   Kondo, S ^b   Tabe, Y ^b   Ohsaka, A ^a,c  

^a JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Isolation; Meropenem; Multidrug resistant; Pseudomonas aeruginosa; Risk factor; Surgery

Indexed keywords

AMIKACIN; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DIABETES MELLITUS; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PREDICTION; PSEUDOMONAS AERUGINOSA; RISK FACTOR; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DIABETES COMPLICATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; LENGTH OF STAY; POSTOPERATIVE COMPLICATIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; THIENAMYCINS;

EID: 84873092022     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2012.10.005     Document Type: Article

References (10)

1. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002, 49:229-233.
2. McGowan J.E. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006, 119(Suppl. 6A):S29-S36.
3. Cohen A.L., Calfee D., Fridkin S.K., et al. Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC position paper. Infect Control Hosp Epidemiol 2008, 29:901-913.
4. Nakamura A., Miyake K., Misawa S., et al. Association between antimicrobial consumption and clinical isolates of methicillin-resistant Staphylococcus aureus: a 14-year study. J Infect Chemother 2012, 18:90-95.
5. Kirikae T., Mizuguchi Y., Arakawa Y. Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. J Antimicrob Chemother 2008, 61:612-615.
6. Doron S., Davidson L.E. Antimicrobial stewardship. Mayo Clin Proc 2011, 86:1113-1123.
7. Cao B., Wang H., Sun H., Zhu Y., Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004, 57:112-118.
8. Ohmagari N., Hanna H., Graviss L., et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005, 104:205-212.
9. Regal R.E., DePestel D.D., VandenBussche H.L. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy 2003, 23:618-624.
10. Goel N., Wattal C., Oberoi J.K., Raveendran R., Datta S., Prasad K.J. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother 2011, 66:1625-1630.